Dyve Announces Poster Presentation at 2023 AACR Annual Meeting

2023-04-17

AACR会议免疫疗法

CAMARILLO, Calif.--(BUSINESS WIRE)-- Dyve Biosciences, Inc. (“Dyve”), a clinical-stage platform biotechnology company with assets in immunology and oncology, today announced that preliminary data from the ongoing pre-clinical partnership with the H. Lee Moffitt Cancer Center & Research Institute Cancer Center & Research Institute will be presented at a poster presentation at the upcoming American Association for Cancer Research (AACR) annual meeting, taking place April 14-19, 2023, in Orlando, Florida. Dyve will present pre-clinical data from its lead oncology drug candidate, DYV800, a pH modulating agent that targets tumor microenvironment (TME) acidity in solid tumors. DYV800, delivered topically to bypass gastrointestinal absorption challenges, neutralizes the TME acidity that plays a strong role in tumor progression (invasion, metastasis, angiogenesis), immune escape, and treatment resistance (radiation, chemotherapy, and immunotherapy). “Dyve continues to advance research in areas where we believe our pH modulation program can achieve the biggest impact for patients and we look forward to sharing new pre-clinical data on our DYV800 program at this year’s AACR. We believe we have a unique delivery approach that can unlock the powerful effects of neutralizing TME acidity, and this dataset is further validation of that,” said Ryan Beal, M.D., Chief Executive Officer, Dyve. Poster Presentation Details: Abstract Title: Transdermal alkalinization treatment induces pH changes in a murine melanoma model as measured with MRI-CEST pH imaging Session Category: Tumor Biology Session Title: Photoacoustic Ultrasound, and Fluorescence Imaging Session Date and Time: Monday, April 17, 2023, 1:30 PM - 5:00 PM Presenter: Dr. Pietro Irrera, H. Lee Moffitt Cancer Center & Research Institute Cancer Center & Research Institute Location: Convention Center, Section 2, Poster Board 13 Abstract Presentation Number: 2391 About Dyve Biosciences, Inc. Dyve Biosciences (“Dyve”) is a clinically validated biotech that is breaking barriers to deliver on the promise of pH modulation. Decades of published research demonstrate that neutralizing microenvironment acidity profoundly impacts disease, with multi-fold improvements in tumor metastases, cancer survival, and immune response. Leveraging our groundbreaking DMAX delivery platform, Dyve’s science directly targets the acidic microenvironments that drive cancer cell growth and inflammation. Dyve has demonstrated that it can deliver intuitive, targeted pH modulation to treat oncologic and immuno-inflammatory diseases. Learn more at .

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构